REFERENCES
1. Gurda BL, Bradbury AM, Vite CH. Canine and feline models of human genetic diseases and their contributions to advancing clinical therapies. Yale J Biol Med. 2017;90:417-31.
2. Bradbury AM, Gurda BL, Casal ML, Ponder KP, Vite CH, Haskins ME. A review of gene therapy in canine and feline models of lysosomal storage disorders. Hum Gene Ther Clin Dev. 2015;26:27-37.
3. Gurda BL, Vite CH. Large animal models contribute to the development of therapies for central and peripheral nervous system dysfunction in patients with lysosomal storage diseases. Hum Mol Genet. 2019;28:R119-31.
4. Platt FM, D’azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4:27.
5. Ludlaim AM, Waddington SN, Mckay TR. Unifying biology of neurodegeneration in lysosomal storage diseases. J Inherit Metab Dis. 2025;48:e12833.
7. Darios F, Stevanin G. Impairment of lysosome function and autophagy in rare neurodegenerative diseases. J Mol Biol. 2020;432:2714-34.
8. Udayar V, Chen Y, Sidransky E, Jagasia R. Lysosomal dysfunction in neurodegeneration: emerging concepts and methods. Trends Neurosci. 2022;45:184-99.
9. Pentchev PG, Comly ME, Kruth HS, et al. A defect in cholesterol esterification in Niemann-Pick disease (type C) patients. Proc. Natl. Acad. Sci. U.S.A. 1985;82:8247-51.
11. Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA. The online metabolic and molecular bases of inherited disease. McGraw-Hill Education; 2019. Available from: https://ommbid.mhmedical.com/book.aspx?bookID=2709 [Last accessed on 12 Jun 2026].
12. Fraldi A, Annunziata F, Lombardi A, et al. Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders. EMBO J. 2010;29:3607-20.
13. Walkley S. Pyramidal neurons with ectopic dendrites in storage diseases exhibit increased GM2 ganglioside immunoreactivity. Neuroscience. 1995;68:1027-35.
15. Zervas M, Somers KL, Thrall MA, Walkley SU. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol. 2001;11:1283-7.
16. Walkley SU, Suzuki K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta. 2004;1685:48-62.
17. Peake KB, Vance JE. Defective cholesterol trafficking in Niemann‐Pick C‐deficient cells. FEBS Lett. 2010;584:2731-9.
18. Vance JE, Peake KB. Function of the Niemann-Pick type C proteins and their bypass by cyclodextrin. Curr Opin Lipidol. 2011;22:204-9.
19. Wojtanik KM, Liscum L. The transport of low density lipoprotein-derived cholesterol to the plasma membrane is defective in NPC1 cells. J Biol Chem. 2003;278:14850-6.
20. Liscum L, Ruggiero RM, Faust JR. The intracellular transport of low density lipoprotein-derived cholesterol is defective in Niemann-Pick type C fibroblasts. J Cell Biol. 1989;108:1625-36.
21. Braak H, Braak E, Goebel HH. Isocortical pathology in type C Niemann-Pick disease: a combined Golgi-Pigmentoarchitectonic study. J Neuropathol Exp Neurol. 1983;42:671-87.
22. Elleder M, Jirásek A, Šmíd F, Ledvinová J, Besley GTN. Niemann-Pick disease type C: study on the nature of the cerebral storage process. Acta Neuropathol. 1985;66:325-36.
23. Lowenthal AC, Cummings JF, Wenger DA, Thrall MA, Wood PA, De Lahunta A. Feline sphingolipidosis resembling Niemann-Pick disease type C. Acta Neuropathol. 1990;81:189-97.
24. Muñana KR, Luttgen PJ, Thrall MA, Mitchell TW, Wenger DA. Neurological Manifestations of Niemann-Pick Disease Type C in Cats. J Vet Intern Med. 1994;8:117-21.
25. Brown DE, Thrall MA, Walkley SU, et al. Feline Niemann-Pick disease type C. Am J Pathol. 1994;144:1412-5.
26. March PA, Thrall MA, Brown DE, Mitchell TW, Lowenthal AC, Walkley SU. GABAergic neuroaxonal dystrophy and other cytopathological alterations in feline Niemann-Pick disease type C. Acta Neuropathol. 1997;94:164-72.
27. Zervas M, Dobrenis K, Walkley SU. Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J Neuropathol Exp Neurol. 2001;60:49-64.
28. Somers KL, Brown DE, Fulton R, et al. Effects of dietary cholesterol restriction in a feline model of Niemann-Pick type C disease. J Inherit Metab Dis. 2001;24:427-36.
30. Vite CH, Ding W, Bryan C, et al. Clinical, electrophysiological, and serum biochemical measures of progressive neurological and hepatic dysfunction in feline Niemann-Pick Type C disease. Pediatr Res. 2008;64:544-9.
31. Bagel JH, Sikora TU, Prociuk M, et al. Electrodiagnostic testing and histopathologic changes confirm peripheral nervous system myelin abnormalities in the feline model of Niemann-Pick disease type C. J Neuropathol Exp Neurol. 2013;72:256-62.
32. Roszell BR, Tao J, Yu KJ, et al. Pulmonary abnormalities in animal models due to Niemann-Pick type C1 (NPC1) or C2 (NPC2) disease. PLoS ONE. 2013;8:e67084.
33. Gurda BL, Bagel JH, Fisher SJ, et al. LC3 Immunostaining in the inferior olivary nuclei of cats with Niemann-Pick disease type C1 is associated with patterned purkinje cell loss. J Neuropathol Exp Neurol. 2018;77:229-45.
34. Porter FD, Scherrer DE, Lanier MH, et al. Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med. 2010;2:56ra81.
35. Tortelli B, Fujiwara H, Bagel JH, et al. Cholesterol homeostatic responses provide biomarkers for monitoring treatment for the neurodegenerative disease Niemann-Pick C1 (NPC1). Hum Mol Genet. 2014;23:6022-33.
36. Fan M, Sidhu R, Fujiwara H, et al. Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling. J Lipid Res. 2013;54:2800-14.
37. Bradbury A, Bagel J, Sampson M, et al. Cerebrospinal fluid calbindin d concentration as a biomarker of cerebellar disease progression in Niemann-Pick type C1 disease. J Pharmacol Exp Ther. 2016;358:254-61.
38. Sidhu R, Kell P, Dietzen DJ, et al. Application of a glycinated bile acid biomarker for diagnosis and assessment of response to treatment in Niemann-Pick disease type C1. Mol Genet Metab. 2020;131:405-17.
39. Mishra S, Kell P, Scherrer D, et al. Accumulation of alkyl-lysophosphatidylcholines in Niemann-Pick disease type C1. J Lipid Res. 2024;65:100600.
40. Stein VM, Crooks A, Ding W, et al. Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C. J Neuropathol Exp Neurol. 2012;71:434-48.
41. Ward S, O’donnell P, Fernandez S, Vite CH. 2-hydroxypropyl-β-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease. Pediatr Res. 2010;68:52-6.
42. Vite CH, Bagel JH, Swain GP, et al. Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease. Sci Transl Med. 2015;7.
43. Kao ML, Stellar S, Solon E, et al. Pharmacokinetics and distribution of 2‐hydroxypropyl‐β‐cyclodextrin following a single intrathecal dose to cats. J Inherit Metab Dis. 2019;43:618-34.
44. Kurokawa Y, Osaka H, Kouga T, et al. Gene therapy in a mouse model of Niemann-Pick disease type C1. Hum Gene Ther. 2021;32:589-98.
45. Davidson CD, Gibson AL, Gu T, et al. Improved systemic AAV gene therapy with a neurotrophic capsid in Niemann-Pick disease type C1 mice. Life Sci. Alliance. 2021;4:e202101040.
46. Hughes MP, Nelvagal HR, Coombe-tennant O, et al. A novel small NPC1 promoter enhances AAV-mediated gene therapy in mouse models of Niemann-Pick Type C1 disease. Cells. 2023;12:1619.
47. Hughes MP, Smith DA, Morris L, et al. AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease. Hum Mol Genet. 2018;27:3079-98.
48. Ory DS, Ottinger EA, Farhat NY, et al. Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. The Lancet. 2017;390:1758-68.
49. Ottinger EA, Kao ML, Carrillo-Carrasco N, et al. Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr Top Med Chem. 2014;14:330-9.
50. Mauler D, Gandolfi B, Reinero C, et al. ; and 99 Lives Consortium. Precision medicine in cats: novel Niemann-Pick type C1 diagnosed by whole-genome sequencing. J Vet Intern Med. 2017;31:539-44.
51. Gutić M, Milosavljević MN, Janković SM. Cost-effectiveness of miglustat versus symptomatic therapy of Niemann-Pick disease type C. Int J Clin Pharm. 2022;44:1442-53.
52. Yoon SY, Hunter JE, Chawla S, et al. Global CNS correction in a large brain model of human alpha-mannosidosis by intravascular gene therapy. Brain. 2020;143:2058-72.
53. Yoon SY, Gay-antaki C, Ponde DE, Poptani H, Vite CH, Wolfe JH. Quantitative, noninvasive, in vivo longitudinal monitoring of gene expression in the brain by co-AAV transduction with a PET reporter gene. Mol Ther Methods Clin Dev. 2014;1:14016.
54. Yoon SY, Bagel JH, O’donnell PA, Vite CH, Wolfe JH. Clinical improvement of alpha-mannosidosis cat following a single cisterna magna infusion of AAV1. Mol Ther. 2016;24:26-33.
55. Hunter JE, Vite CH, Molony CM, O’donnell PA, Wolfe JH. Intracisternal vs intraventricular injection of AAV1 result in comparable, widespread transduction of the dog brain. Gene Ther. 2024;32:184-8.
56. Hunter JE, Molony CM, Panek WK, et al. Effect of disease progression on CSF-directed AAV gene therapy in a large brain animal model of lysosomal storage disease. Mol Ther Methods Clin Dev. 2025;33:101552.
57. Hunter JE, Molony CM, Bagel JH, et al. Widespread correction of brain pathology in feline alpha-mannosidosis by dose escalation of intracisternal AAV vector injection. Mol Ther Methods Clin Dev. 2024;32:101272.
58. Vite CH, Passini MA, Haskins ME, Wolfe JH. Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther. 2003;10:1874-81.
59. Bradbury AM, Bagel JH, Nguyen D, et al. Krabbe disease successfully treated via monotherapy of intrathecal gene therapy. J Clin Investig. 2020;130:4906-20.
60. Muto Y, Suzuki M, Takei H, et al. Dried blood spot-based newborn screening for bile acid synthesis disorders, Zellweger spectrum disorder, and Niemann-Pick type C1 by detection of bile acid metabolites. Mol Genet Metab. 2023;140:107703.
61. Costa Verdera H, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther. 2020;28:723-46.
62. Fratantoni JC, Hall CW, Neufeld EF. Hurler and hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science. 1968;162:570-2.
63. De Marchi F, Munitic I, Vidatic L, et al. Overlapping neuroimmune mechanisms and therapeutic targets in neurodegenerative disorders. Biomedicines. 2023;11:2793.
64. Chu T, Tu X, Yang K, Wu J, Repa JJ, Yan N. Tonic prime-boost of STING signalling mediates Niemann-Pick disease type C. Nature. 2021;596:570-5.
65. Azaria RD, Correia AB, Schache KJ, et al. Mutant induced neurons and humanized mice enable identification of Niemann-Pick type C1 proteostatic therapies. JCI Insight. 2024;9:e179525.
66. Murray CE, Betancourt-trompa DS, Martinez MS, et al. Role of mTORC1 signaling in postnatal microglia activation preceding neurodegeneration in a mouse model for Niemann-Pick disease Type C. PLoS ONE. 2025;20:e0330437.
67. Gascón-bayarri J, Rico I, Sánchez-castañeda C, et al. Efficacy and safety of efavirenz in Niemann-Pick disease type C. Neurotherapeutics. 2025;22:e00706.
68. Shammas H, Kloster Fog C, Klein P, et al. Mechanistic insights into arimoclomol mediated effects on lysosomal function in Niemann-Pick type C disease. Mol Genet Metab. 2025;145:109103.
69. Patterson MC, Ramaswami U, Donald A, et al. Disease-modifying, neuroprotective effect of N-Acetyl-l-leucine in adult and pediatric patients with Niemann-Pick disease type C. Neurology. 2025;105:e213589.
70. Stee K, Van Poucke M, Lowrie M, et al. Phenotypic and genetic aspects of hereditary ataxia in dogs. J Vet Intern Med. 2023;37:1306-22.
71. Casazza K, Cologna SM, Berry‐kravis E, Jarnes J, Porter FD. Biomarker Validation inNPC1: foundations for clinical trials and regulatory alignment. J Inherit Metab Dis. 2025;48:e70075.
